Literature DB >> 10636162

Apomorphine can sustain the long-duration response to L-DOPA in fluctuating PD.

J G Nutt1, J H Carter.   

Abstract

The authors investigated the ability of daytime infusions of apomorphine, a D-1 and D-2 dopamine agonist, to sustain the long-duration response (LDR) in seven subjects with fluctuating PD in whom L-DOPA was discontinued for 3 days. Apomorphine maintained the LDR to the extent that it kept the subjects "on" during the day. This observation suggests that the LDR can be a postsynaptic effect, independent of dopamine storage.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10636162     DOI: 10.1212/wnl.54.1.247

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  10 in total

Review 1.  Preservation of function in Parkinson's disease: what's learning got to do with it?

Authors:  Jeff A Beeler
Journal:  Brain Res       Date:  2011-09-29       Impact factor: 3.252

2.  Pharmacokinetic and pharmacodynamic changes during the first four years of levodopa treatment in Parkinson's disease.

Authors:  Phylinda L S Chan; John G Nutt; Nicholas H G Holford
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-08       Impact factor: 2.745

3.  A 5-year prospective assessment of advanced Parkinson disease patients treated with subcutaneous apomorphine infusion or deep brain stimulation.

Authors:  Angelo Antonini; Ioannis U Isaias; Giorgia Rodolfi; Andrea Landi; Francesca Natuzzi; Chiara Siri; Gianni Pezzoli
Journal:  J Neurol       Date:  2010-10-23       Impact factor: 4.849

Review 4.  The role of the long-duration response to levodopa in Parkinson's disease.

Authors:  Mario Zappia; Alessandra Nicoletti
Journal:  J Neurol       Date:  2010-11       Impact factor: 4.849

Review 5.  The missing, the short, and the long: Levodopa responses and dopamine actions.

Authors:  Roger L Albin; Daniel K Leventhal
Journal:  Ann Neurol       Date:  2017-06-05       Impact factor: 10.422

Review 6.  Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.

Authors:  Dirk Deleu; Yolande Hanssens; Margaret G Northway
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

Review 7.  Potential of transdermal drug delivery in Parkinson's disease.

Authors:  Ronald F Pfeiffer
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

Review 8.  Drug-Induced Dyskinesia, Part 1: Treatment of Levodopa-Induced Dyskinesia.

Authors:  Dhanya Vijayakumar; Joseph Jankovic
Journal:  Drugs       Date:  2016-05       Impact factor: 9.546

9.  Current approaches to the treatment of Parkinson's disease.

Authors:  Joseph Jankovic; L Giselle Aguilar
Journal:  Neuropsychiatr Dis Treat       Date:  2008-08       Impact factor: 2.570

Review 10.  Apomorphine and levodopa infusion therapies for advanced Parkinson's disease.

Authors:  Angelo Antonini
Journal:  J Mov Disord       Date:  2009-04-30
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.